16.83
+0.345(+2.09%)
Currency In USD
| Previous Close | 16.48 |
| Open | 16.47 |
| Day High | 16.93 |
| Day Low | 16.41 |
| 52-Week High | 35.84 |
| 52-Week Low | 15.7 |
| Volume | 247,297 |
| Average Volume | 465,943 |
| Market Cap | 485.78M |
| PE | 28.52 |
| EPS | 0.59 |
| Moving Average 50 Days | 19.53 |
| Moving Average 200 Days | 26.45 |
| Change | 0.35 |
If you invested $1000 in Castle Biosciences, Inc. (CSTL) since IPO date, it would be worth $786.21 as of May 16, 2025 at a share price of $16.825. Whereas If you bought $1000 worth of Castle Biosciences, Inc. (CSTL) shares 5 years ago, it would be worth $471.95 as of May 16, 2025 at a share price of $16.825.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result
GlobeNewswire Inc.
May 09, 2025 11:00 AM GMT
FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recentl
Castle Biosciences Celebrates Skin Cancer Awareness Month
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
At just 26 years old, Leah Adams heard the words no one wants to hear: malignant melanoma. In this powerful and emotional story, Leah shares how a routine skin check—prompted by her mother’s intuition—led to a life-altering diagnosis. As a runn
Castle Biosciences to Acquire Previse
GlobeNewswire Inc.
May 05, 2025 8:05 PM GMT
Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE)